August 11, 2021
Preliminary clinical results in deadly forms of breast and ovarian cancers have encouraged oncologists to expand the study to include hormone-resistant breast and metastatic prostate cancers; at the center of the study is CureLab Oncology’s Elenagen, an experimental DNA therapy
July 20, 2021
Patent makes it feasible to commence clinical trials to establish effectiveness of its lead product and product variations for treatment of neurodegenerative diseases Patent makes it feasible to commence clinical trials to establish effectiveness of its lead product and product variations for treatment of neurodegenerative diseases
June 30, 2021
CureLab Oncology intends to determine whether its Elenagen DNA vaccine can be used to reduce severity, mortality and life-threatening post-COVID complications.
March 15, 2021
Patent registration in Hong Kong paves the way to establishing business operations in PRC
January 22, 2021
Based on a scientifically solid proof of concept in dogs and cats, an international IP portfolio, and a comprehensive scientific advisory board that includes key opinion leaders and experienced management, CureLab Veterinary intends to raise initial financing through a crowdfunding campaign set to launch within a month, and to become profitable within 36 months of raising funds.